Canadian research breakthrough holds promise for development of effective cancer therapiesSeptember 03, 2009Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies. A recent article co-authored by Drs. Therrien and Sicheri and published in the leading scientific journal Nature sheds new light on the activation mechanism of the RAF protein kinase which, when mutated, is responsible for more than 25 per cent of cancers. Understanding this mechanism may lead to novel anti-cancer agents designed to minimize the toxic side effects caused by chemotherapy. The RAF family of kinases regulates various cellular processes including cell growth, differentiation and survival. The Therrien-Sicheri team is the first to show that the dimerization, or combination, of two RAF proteins is essential to its activation. Inhibiting the dimerization of RAF may therefore block its activation, thus stopping cancer cells from growing. The study exposes not only the activation mechanism of RAF, but potentially the mechanisms that control other protein kinases, a large number of which are linked to cancer and other diseases such as diabetes, hypertension and neurodegeneration. "Basic researchers believe that one of the most promising strategies to finding lifelong cures for cancers lies in understanding the molecular underpinnings specific to cancer cells," explains Dr. Therrien, "It is hoped that this will translate to the development of inhibitors tailored to specific molecular defects and, as a result, should increase the effectiveness of new target-based cancer therapies." "Protein kinases are the targets for some of the most successful anti-cancer drugs in the clinic," says Dr. Sicheri. "Now that we have discovered how to turn off the RAF protein without interfering with other proteins, we may be able to design drugs that have unprecedented precision in targeting cancer cells while reducing the toxic side effects for patients." The Therrien-Sicheri team intends to jointly pursue work in this area to identify drug-like molecules to block the dimerization process of RAF, which may possibly lead to the discovery of new classes of anti-cancer agents. University of Montreal |
|||||||||||||||||||||
| Related Cancer Therapies Current Events and Cancer Therapies News Articles New cancer target for non-Hodgkin's lymphoma Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. Bioluminescence imaging used for eye cancer detection At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery. Transcendental meditation reduces stress, improves mental health among women with breast cancer Women with breast cancer reduced stress and improved their mental health and emotional well being through the Transcendental Meditation technique. Penn studies point to strategies for reducing painful breast cancer drug side effects Aromatase inhibitors, the same drugs that have buoyed long-term survival rates among breast cancer patients, also carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines. Casting out devils In the scientific journal PLoS ONE, Sara Bartels and Siegfried Weiss of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany now show how the bacteria migrate into tumours. Natural compounds, chemotherapeutic drugs may become partners in cancer therapy Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy. Unlocking the body's defenses against cancer Scientists have discovered a way of allowing healthy cells to take charge of cancerous cells and stop them developing into tumours in what could provide a new approach to treating early-stage cancers. First compound that specifically kills cancer stem cells found The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all. Multi-laboratory study sizes up nanoparticle sizing As a result of a major inter-laboratory study, the standards body ASTM International has been able to update its guidelines for a commonly used technique for measuring the size of nanoparticles in solutions. STAT3 Gene Regulates Cancer Stem Cells in Brain Cancer In a study published online in advance of print in Stem Cells, Tufts researchers report that the STAT3 gene regulates cancer stem cells in brain cancer. Cancer stem cells have many characteristics of stem cells and are thought to be the cells that drive tumor formation. More Cancer Therapies Current Events and Cancer Therapies News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||